9月1日，港股荣昌生物（09995.HK）股价表现强劲，盘中大涨5.04%，引起投资者广泛关注。该股今日早盘就呈现上涨态势，截至发稿时已突破100港元大关。
荣昌生物近期发布的中期业绩显示，公司上半年业绩表现亮眼。营业收入达到10.9亿元，同比增长48%；归母净利润虽仍亏损4.5亿元，但同比减亏3.3亿元，显示公司经营状况明显改善。光大证券分析指出，公司营收增长主要得益于核心产品泰它西普和维迪西妥单抗销量的持续增加。
值得注意的是，机构对荣昌生物的前景持乐观态度。在13家参与评级的机构中，超过半数（54%）给予买入建议。此外，8月29日南向资金增持该股192.70万股，显示机构投资者对公司发展前景充满信心。分析人士认为，随着核心产品放量和研发管线推进，荣昌生物有望继续保持良好的增长势头。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.